2025 annual financial data
Xilio Therapeutics 2025 Operating margin
Direct answer
Operating margin was -95.92%.
Operating income was -41,982,000 USD and net income was -35,036,000 USD.
Operating cash flow was -4,992,000 USD.
Get free Xilio Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 43,766,000 USD
- Operating income
- -41,982,000 USD
- Net income
- -35,036,000 USD
- Operating cash flow
- -4,992,000 USD